November 22, 2016 7:35am
… After the past the past five sessions, I’d be “booking” any gain and departing for Thanksgiving as early as I could get away …
I answer one question; in which company should investors put, keep and commit their money!
If you are not a subscriber, you won’t know the morning’s indications and who is in the headlights.
I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!
RegMed Investors’ (RMi) provides exclusive and original content; put your eyes on the page to figure out what’s really going on!
I keep track of closes, indexes and pricing as news lately lacks any energy as the social media impact of RMi reporting stimulates the reality of “our” universe as well as disrupting element in the trading of sector equities!
SELL: IMUC, AST, BLCM, CAPR, OPXA and KITE
Indexes and ETFs: The IBB (+0.17%), XLV (+0.20) and IWM (+0.36%) are UP and XBI is NOT indicating
Dow futures are UP +0.25% and NASDAQ futures are UP +0.46%
U.S. stock index futures pointed to a higher open on Tuesday after the four major market indexes all closed at record highs in the previous session.
Europe markets started higher, following record highs on Wall Street and expectations that OPEC members will reach an agreement over an output cut.
Asian markets rallied as the dollar retreated as Japanese shares turned positive after damage from an earthquake appeared moderate.
Data docket: existing home sales for October as well as a Richmond Fed survey for November, both released at 10 a.m. ET.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Monday, Friday and Thursday, NEGATIVE Wednesday and last Tuesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Monday closed POSITIVE with 15 decliners, 27 advancers and 1 flat;
· Friday closed POSITIVE with 17 decliners, 24 advancers and 2 flats;
· Thursday closed POSITIVE with 15 decliners, 28 advancers and 0 flats;
· Wednesday closed NEGATIVE with 26 decliners, 13 advancers and 4 flats;
· Last Tuesday closed NEGATIVE with 27 decliners, 13 advancers and 3 flats;
Remembering Monday’s closing investor letter, “The sector flipped positive in the session’s last hour! While testing volume, moving averages, fundamentals, resistance and expectation … And with tight trading ranges>’
As I had stated, “A pause for reflection could come as Tuesday closes and when volume traditionally thins out as traders head out for the Thanksgiving Day holiday. “
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Monday up +0.70% and is UP +0.17% in Tuesday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Monday up +0.58% and is NOT indicating in Tuesday pre-market;
· The Health Care Select Sector SPDR ETF (XLV) closed up +0.36% Monday and is UP +0.20% in Tuesday’s pre-market;
· The iShares Russell 2000 (IWM) closed up +0.53% on Monday and is UP +0.36% in Tuesday’s pre-market.
Companies in my headlights:
Asterias Biotherapeutics (NYSEMKT: AST) closed UP again +$0.09 to $5.65 following Friday’s $5.56 (+$0.11) after Thursday’s $5.45 (+$0.65) after Wednesday’s $4.80 (+$0.40). Since 11/8’s $3.05 to 11/15’s <Tuesday> $4.40, a target is being formed for trading – Maintaining SELL;
Bellicum Pharmaceuticals (BLCM) closed UP again +$0.28 to $22.80 following Friday’s $22.52 (+$0.49). Momentum traders catch the essence of a trade, as the week staggered across trades $22.02 <Thursday>, $21.95 <Wednesday>, $22.32 <Tuesday>, and Monday’s $22.69. While the previous week 11/4-7 laid the course at $17.75 to $22.14 – Maintaining SELL;
Capricor (CAPR) closed UP +$0.0.025 to $3.175 following Friday’s $3.15 (+$0.06). After a decent week of Thursday’s $3.09, Wednesday’s $2.95, Tuesday’s $3.00 and Monday’s $3.11 while the previous week’s ranged from $2.66 to $2.87. I’d SELL to come back … I still have questions re their spending and the issue of patent filling on their newest quest for exosomes; also the Janssen (J&J) option is yet to be secured … Maintaining SELL;
ImmunoCellular (NYSEMKT: IMUC) closed UP +$3.235 or +4938.17% to $3.30 following Friday’s $0.065 (-$0.0046). IMUC common stock and listed warrants began trading Monday on the NYSE MKT on a split-adjusted basis – a one-for-forty reverse stock split. Concurrently, the authorized number of shares of IMUC's common stock will be reduced from 249 M to 25 M. Watch for the downside sell-off … SELL;
Kite Pharma (KITE) closed UP +$1.88 to $53.68. Take “some” off the table, after a run from Friday’s $51.80, Thursday’s $50.56 and Wednesday’s $50.11. Be safe, I don’t trust rebounds that usually reverberate – SELL;
Opexa (OPXA) closed UP +$0.80 to $1.47. The jump from $0.67 <Friday>, $0.55 <Thursday>, $0.55 <Wednesday’s $0.59, Tuesday and Monday’s $0.56 – it’s a turkey. The aftermarket indication is negative -$0.02 – SELL;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
